FDA Panel Backs First Radio-Frequency Asthma Treatment
By wchung | 18 Jun, 2026
Federal health advisers are recommending a novel technology from Asthmatx be approved as the first non-drug treatment for asthma.
The Food and Drug Administration’s panel of respiratory device experts voted 6-1 that Asthmatx’s Alair System be approved under certain conditions, including long-term tracking of patients.
The company’s procedure, called thermoplasty, uses extreme heat to burn away lung tissue that makes it difficult to breath and causes coughing spasms and wheezing. The heat is delivered via a catheter that emits radiofrequency waves, dissolving excess muscle.
While roughly 20 million people in the U.S. suffer from asthma, thermoplasty would only be appropriate for about 2 million adults who don’t get relief from existing drugs.
10/28/2009 5:06 PM WASHINGTON (AP)
Recent Articles
- Global Demand Surges for Anti-Drone Technology
- BYD Looks to Formula One for Fast Global Brand Expansion
- Europe's EV Sales Keep Growing As Fuel Costs Rise, Car Prices Fall
- SK Hynix Ships Samples of Next-Generation AI HBM Chips
- Apple to Raise Prices Due to Memory Chip Shortage
- Trump Scraps Four More Offshore Wind Leases with $765 Million Refund
- Oil Roundtrips, AI Booms, US Consumers Spend, Economists' Fed Outlooks Go Wild
- Trump Endorsee Loses in Georgia Governor's Primary Race
- BMW Shares Sink After Profit Warning Highlights China and Iran Risk
- AI Will Lead to Labour Shortages, Bezos Says at Paris Conference
